Drug-induced osteoporosis: from Fuller Albright to aromatase inhibitors

References

• International Osteoporosis Foundation. Osteoporosis. 2015, Viewed 2015 August 22. Available from: http://www.iofbonehealth.org/osteoporosis
   Google Scholar
• Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int 2014;25:2359–81
   PubMed Web of Science ®Google Scholar
• Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 2007;22:465–75
   PubMed Web of Science ®Google Scholar
• Suzman R, Beard J. Global health and aging. National Institute on Aging. 2011. Viewed 2015 August 22. Available from: https://d2cauhfh6h4x0p.cloudfront.net/s3fs-public/global_health_and_aging.pdf
   Google Scholar
• Brooks B. Top 100 most prescribed, top-selling drugs. Medscape 2014. Viewed 2015 August 22. Available from: http://www.medscape.com/viewarticle/829246
   Google Scholar
• Pitts CJ, Kearns AE. Update on medications with adverse skeletal effects. Mayo Clin Proc 2011;86:338–43
   PubMed Web of Science ®Google Scholar
• Panday K, Gona A, Humphrey MB. Medication-induced osteoporosis: screening and treatment strategies. Ther Adv Musculoskelet Dis 2014;6:185–202
   PubMedGoogle Scholar
• Albright F, Smith PH, Richardson AM. Postmenopausal osteoporosis: its clinical features. JAMA 1941;116:2465–74
   Google Scholar
• Reifenstein EC Jr, Albright F. The metabolic effects of steroid hormones in osteoporosis. J Clin Invest 1947;26:24–56
   PubMed Web of Science ®Google Scholar
• Reifenstein EC Jr, Albright F. The classic: the metabolic effects of steroid hormones in osteoporosis. 1946. Clin Orthop Relat Res 2011;469:2096–127
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Frenkel B, White W, Tuckermann J. Glucocorticoid-induced osteoporosis. Adv Exp Med Biol 2015;872:179–215
   PubMed Web of Science ®Google Scholar
• Silverman SL, Lane NE. Glucocorticoid-induced osteoporosis. Curr Osteoporos Rep 2009;7:23–6
   PubMedGoogle Scholar
• Mazzantini M, Di Munno O. Glucocorticoid-induced osteoporosis: 2013 update. Reumatismo 2014;66:144–52
   PubMedGoogle Scholar
• Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010;62:1515–26
   PubMed Web of Science ®Google Scholar
• Briot K, Cortet B, Roux C, et al. 2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. Joint Bone Spine 2014;81:493–501
   PubMed Web of Science ®Google Scholar
• Lekamwasam S, Adachi JD, Agnusdei D, et al. An appendix to the 2012 IOF-ECTS guidelines for the management of glucocorticoid-induced osteoporosis. Arch Osteoporos 2012;7:25–30
   PubMedGoogle Scholar
• Lekamwasam S, Adachi JD, Agnusdei D, et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 2012;23:2257–76
   PubMed Web of Science ®Google Scholar
• Duru N, van der Goes MC, Jacobs JW, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2013;72:1905–13
   PubMed Web of Science ®Google Scholar
• Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health 2013;34:119–38
   PubMed Web of Science ®Google Scholar
• Goltzman D. LRP5, serotonin, and bone: Complexity, contradictions, and conundrums. J Bone Miner Res 2011;26:1997–2001
   PubMed Web of Science ®Google Scholar
• Ducy P, Karsenty G. The two faces of serotonin in bone biology. J Cell Biol 2010;191:7–13
   PubMed Web of Science ®Google Scholar
• Diem SJ, Blackwell TL, Stone KL, et al. Use of antidepressant medications and risk of fracture in older women. Calcif Tissue Int 2011;88:476–84
   PubMed Web of Science ®Google Scholar
• Williams LJ, Henry MJ, Berk M, et al. Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. Int Clin Psychopharmacol 2008;23:84–7
   PubMed Web of Science ®Google Scholar
• Haney EM, Chan BK, Diem SJ, et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 2007;167:1246–51
   PubMed Web of Science ®Google Scholar
• Ginzburg R, Rosero E. Risk of fractures with selective serotonin-reuptake inhibitors or tricyclic antidepressants. Ann Pharmacother 2009;43:98–103
   PubMed Web of Science ®Google Scholar
• Rabenda V, Bruyere O, Reginster JY. Risk of nonvertebral fractures among elderly postmenopausal women using antidepressants. Bone 2012;51:674–9
   PubMed Web of Science ®Google Scholar
• Bakken MS, Engeland A, Engesaeter LB, et al. Increased risk of hip fracture among older people using antidepressant drugs: data from the Norwegian Prescription Database and the Norwegian Hip Fracture Registry. Age Ageing. 2013;42:514–20
   PubMed Web of Science ®Google Scholar
• Prieto-Alhambra D, Petri H, Goldenberg JS, et al. Excess risk of hip fractures attributable to the use of antidepressants in five European countries and the USA. Osteoporos Int 2014;25:847–55
   PubMed Web of Science ®Google Scholar
• Moura C, Bernatsky S, Abrahamowicz M, et al. Antidepressant use and 10-year incident fracture risk: the population-based Canadian Multicentre Osteoporosis Study (CaMoS). Osteoporos Int 2014;25:1473–81
   PubMed Web of Science ®Google Scholar
• Rabenda V, Nicolet D, Beaudart C, et al. Relationship between use of antidepressants and risk of fractures: a meta-analysis. Osteoporos Int 2013;24:121–37
   PubMed Web of Science ®Google Scholar
• Eom CS, Lee HK, Ye S, et al. Use of selective serotonin reuptake inhibitors and risk of fracture: a systematic review and meta-analysis. J Bone Miner Res 2012;27:1186–95
   PubMed Web of Science ®Google Scholar
• Lanteigne A, Sheu YH, Sturmer T, et al. Serotonin-norepinephrine reuptake inhibitor and selective serotonin reuptake inhibitor use and risk of fractures: a new-user cohort study among US adults aged 50 years and older. CNS Drugs 2015;29:245–52
   PubMed Web of Science ®Google Scholar
• Haney EM, Warden SJ, Bliziotes MM. Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management? Bone 2010;46:13–17
   PubMed Web of Science ®Google Scholar
• Bruyere O, Reginster JY. Osteoporosis in patients taking selective serotonin reuptake inhibitors: a focus on fracture outcome. Endocrine 2015;48:65–8
   PubMed Web of Science ®Google Scholar
• Gebara MA, Shea ML, Lipsey KL, et al. Depression, antidepressants, and bone health in older adults: a systematic review. J Am Geriatr Soc 2014;62:1434–41
   PubMed Web of Science ®Google Scholar
• Fraser LA, Leslie WD, Targownik LE, et al. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int 2013;24:1161–8
   PubMed Web of Science ®Google Scholar
• Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947–53
   PubMed Web of Science ®Google Scholar
• Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008;83:251–9
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006;79:76–83
   PubMed Web of Science ®Google Scholar
• Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone 2011;48:768–76
   PubMed Web of Science ®Google Scholar
• Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010;139:93–101
   PubMed Web of Science ®Google Scholar
• Targownik LE, Leslie WD. The relationship among proton pump inhibitors, bone disease and fracture. Expert Opin Drug Saf 2011;10:901–12
   PubMed Web of Science ®Google Scholar
• Lewis JR, Barre D, Zhu K, et al. Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study. J Bone Miner Res 2014;29:2489–97
   PubMed Web of Science ®Google Scholar
• Yang YX. Chronic proton pump inihibitor therapy and calcium metabolism. Curr Gastroenterol Rep 2012;14:473–9
   PubMedGoogle Scholar
• International Diabetes Federation. IDF Diabetes Atlas, 6th edn. International Diabetes Federation, 2014
   Google Scholar
• Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007;166:495–505
   PubMed Web of Science ®Google Scholar
• Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab 2006;91:3404–10
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427–43
   PubMed Web of Science ®Google Scholar
• Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008;31:845–51
   PubMed Web of Science ®Google Scholar
• Bilezikian JP, Josse RG, Eastell R, et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013;98:1519–28
   PubMed Web of Science ®Google Scholar
• Berberoglu Z, Gursoy A, Bayraktar N, et al. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 2007;92:3523–30
   PubMed Web of Science ®Google Scholar
• Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009;180:32–9
   PubMed Web of Science ®Google Scholar
• Akune T, Ohba S, Kamekura S, et al. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004;113:846–55
   PubMed Web of Science ®Google Scholar
• Grey A. Thiazolidinedione-induced skeletal fragility – mechanisms and implications. Diabetes Obes Metab 2009;11:275–84
   PubMed Web of Science ®Google Scholar
• Giangregorio LM, Leslie WD, Lix LM, et al. FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res 2012;27:301–8
   PubMed Web of Science ®Google Scholar
• Leslie WD, Rubin MR, Schwartz AV, Kanis JA. Type 2 diabetes and bone. J Bone Miner Res 2012;27:2231–7
   PubMed Web of Science ®Google Scholar
• Chumsri S. Clinical utilities of aromatase inhibitors in breast cancer. Int J Womens Health 2015;7:493–9
   PubMedGoogle Scholar
• Hadji P. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 2009;69:73–82
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Effect of tamoxifen and aromatase inhibitors on the risk of fractures in women with breast cancer. CalcifTissue Int 2008;82:334–40
   PubMed Web of Science ®Google Scholar
• Hadji P, Aapro MS, Body JJ, et al. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 2011;22:2546–55
   PubMed Web of Science ®Google Scholar
• Lester JE, Dodwell D, Purohit OP, et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008;14:6336–42
   PubMed Web of Science ®Google Scholar
• Confavreux CB, Fontana A, Guastalla JP, et al. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 2007;41:346–52
   PubMed Web of Science ®Google Scholar
• Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007;25:829–36
   PubMed Web of Science ®Google Scholar
• Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008;9:840–9
   PubMed Web of Science ®Google Scholar
• Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008;26:4875–82
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132–9
   PubMed Web of Science ®Google Scholar
• Body JJ, Bergmann P, Boonen S, et al. Management of cancer treatment-induced bone loss in early breast and prostate cancer – a consensus paper of the Belgian Bone Club. Osteoporos Int 2007;18:1439–50
   PubMed Web of Science ®Google Scholar
• Reid DM, Doughty J, Eastell R, et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 2008;34(Suppl 1):S3–18
   PubMedGoogle Scholar
• Rizzoli R, Body JJ, DeCensi A, et al. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Osteoporos Int 2012;23:2567–76
   PubMed Web of Science ®Google Scholar
• Gralow JR, Biermann JS, Farooki A, et al. NCCN Task Force Report: Bone Health In Cancer Care. J Natl Compr Canc Netw 2013;11(Suppl 3):S1–50
   PubMed Web of Science ®Google Scholar
• Kanis JA, Oden A, Johansson H, et al. FRAX(R) and its applications to clinical practice. Bone 2009;44:734–43
   PubMed Web of Science ®Google Scholar
• Potosky AL, Haque R, Cassidy-Bushrow AE, et al. Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. J Clin Oncol 2014;32:1324–30
   PubMed Web of Science ®Google Scholar
• Garcia JA, Rini BI. Castration-resistant prostate cancer: many treatments, many options, many challenges ahead. Cancer 2012;118:2583–93
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. II. Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65:467–79
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Coates P, Sereika SM, et al. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005;90:6410–17
   PubMed Web of Science ®Google Scholar
• Stoch SA, Parker RA, Chen L, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 2001;86:2787–91
   PubMed Web of Science ®Google Scholar
• Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154–64
   PubMed Web of Science ®Google Scholar
• Smith MR, Lee WC, Brandman J, et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005;23:7897–903
   PubMed Web of Science ®Google Scholar
• Bilezikian JP. Osteoporosis in men. J Clin Endocrinol Metab 1999;84:3431–4
   PubMed Web of Science ®Google Scholar
• Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948–55
   PubMed Web of Science ®Google Scholar
• Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007;25:1038–42
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007;146:416–24
   PubMed Web of Science ®Google Scholar
• Smith MR, Malkowicz SB, Chu F, et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 2008;179:152–5
   PubMed Web of Science ®Google Scholar
• Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:3841–6
   PubMed Web of Science ®Google Scholar
• Smith MR, Egerdie B, Hernandez TN, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745–55
   PubMed Web of Science ®Google Scholar
• Smith MR, Morton RA, Barnette KG, et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol 2010;184:1316–21
   PubMed Web of Science ®Google Scholar
• Ito K, Elkin EB, Girotra M, Morris MJ. Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med 2010;152:621–9
   PubMed Web of Science ®Google Scholar
• Snedecor SJ, Carter JA, Kaura S, Botteman MF. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis. J Med Econ 2013;16:19–29
   PubMedGoogle Scholar
• Stopeck A, Rader M, Henry D, et al. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ 2012;15:712–23
   PubMedGoogle Scholar
• US Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General, 2004
   Google Scholar